Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer.

ABSTRACT:

Purpose

Regorafenib, an oral multikinase inhibitor, has demonstrated survival benefit in metastatic colorectal cancer (mCRC) patients that have progressed after all standard therapies. However, novel strategies to improve tolerability and enhance anti-cancer efficacy are needed.

Experimental design

We have evaluated in vitro the effects of regorafenib in combination with silybin, a biologically active component extracted from the seeds of Silybum marianum, in a panel of human colon cancer cells. Furthermore, we have prospectively treated a cohort of 22 refractory mCRC patients with regorafenib plus silybin.

Results

Treatment with regorafenib determined a dose-dependent growth inhibition whereas treatment with silybin had no anti-proliferative effects among all

SUBMITTER: Belli V 

PROVIDER: S-EPMC5620258 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature